Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 32Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 16Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Colorectal Neoplasms 11Sarcoma 9Lung Neoplasms 9Nasopharyngeal Carcinoma 7Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Head and Neck Neoplasms 5Glioma 5Esophageal Neoplasms 5Cholangiocarcinoma 5Recurrence 4Pancreatic Neoplasms 4Osteosarcoma 4Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Advanced Gastric Cancer 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Neoplasm Metastasis 3NSCLC 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

camrelizumab 2apatinib 2S 1 (combination) 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Metastatic Gastric Adenocarcinoma × apatinib × Clear all
NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡